Literature DB >> 678316

Mode of action of the lipid-lowering agents, clofibrate and BM 15075, on cholesterol biosynthesis in rat liver.

J Berndt, R Gaumert, J Still.   

Abstract

When rats were fed a diet containing 0.3% clofibrate or a derivative of this drug, BM 15075, serum cholesterol was lowered within 3-7 days by 26-38%. Both drugs diminished the activity of hydroxymethylglutaryl CoA reductase, the regulatory enzyme of hepatic cholesterol biosynthesis, in rat liver microsomes by about 60% under the same conditions. The decrease in the activity of the enzyme obviously is due to changes in the amount of enzyme protein. Under in vitro conditions microsomal hydroxymethylglutaryl CoA reductase was inhibited competitively by (1.35 mM) clofibric acid (sodium salt) and by BM 15075 (1 mM) with respect to its substrate. These results give evidence that these drugs can affect both, the rate of synthesis and the substrate affinity of hydroxymethylglutaryl CoA reductase.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678316     DOI: 10.1016/0021-9150(78)90057-6

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  14 in total

1.  Effect of clofibrate on brain mevalonate-5-pyrophosphate decarboxylase.

Authors:  M F Zafra; S Riquelme; M Castillo; E Garcia-Peregrin
Journal:  Neurochem Res       Date:  1987-09       Impact factor: 3.996

2.  Hypocholesterolemic activity of racemic dichlorophenoxypropionic acid or its enantiomers in rats.

Authors:  F Ohta; F Gaudemer; C Lutton
Journal:  Bull Environ Contam Toxicol       Date:  1987-12       Impact factor: 2.151

3.  Reduction of BM 15.766-induced 7-dehydrocholesterol accumulation by bezafibrate and mevinolin in rats. A non-isotopic in vivo test system for compounds reducing cholesterol synthesis.

Authors:  J Pill; E C Witte; F H Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

4.  Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

Authors:  J Shepherd; C J Packard; J M Stewart; R F Atmeh; R S Clark; D E Boag; K Carr; A R Lorimer; D Ballantyne; H G Morgan
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

5.  Hypolipidemic drugs are inhibitors of phosphatidylcholine synthesis.

Authors:  S Parthasarathy; D Kritchevsky; W J Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia.

Authors:  L D Curtis; A C Dickson; K L Ling; J Betteridge
Journal:  BMJ       Date:  1988-07-16

7.  Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia.

Authors:  P Weisweiler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 8.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

9.  Hypolipidemic effects of clofibrate and selected chroman analogs in fasted rats: I. Chow-fed animals.

Authors:  M O'Brien; S T Patel; A Mukhopadhyay; H A Newman; D R Feller; S S Kokrady; D T Witiak; R R Lanese; J C Rice
Journal:  Lipids       Date:  1981-12       Impact factor: 1.880

10.  Regulation of bile acid and cholesterol metabolism by PPARs.

Authors:  Tiangang Li; John Y L Chiang
Journal:  PPAR Res       Date:  2009-07-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.